Connect with us

Technology

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Published

4 months ago

on

BEIJING, July 19, 2024 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:

https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.

CASI Forward-Looking Statements:

This announcement and the current report on Form 6-K contain forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the business outlook and quotations from management in this announcement and the current report on Form 6-K, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided herein is as of the date of this announcement and the current report on Form 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN® is proprietary to Acrotech Biopharma Inc and its affiliates.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-development-relating-to-its-disputes-with-juventas-302201852.html

SOURCE CASI Pharmaceuticals, Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

O’Fallon (MO) Police Department Revolutionizes Public Safety with Cutting-Edge Technology with Caliber Public Safety

Published

3 hours ago

on

November 17, 2024

By

O’Fallon (MO) Police Department is enhancing public safety by adopting Caliber’s public safety software suite, positioning itself as a leader in modern public safety technology.

WINSTON-SALEM, N.C., Nov. 17, 2024 /PRNewswire-PRWeb/ — O’Fallon, MO – The O’Fallon Police Department is proud to announce its partnership with Caliber Public Safety, integrating state-of-the-art Computer-Aided Dispatch (CAD), Records Management System (RMS), and Mobile solutions to enhance public safety and law enforcement operations.

“We’re honored to partner with the O’Fallon Police Department in their innovative approach to public safety, empowering their mission to boost efficiency and protect their community,” said Chris Faircloth, VP of Sales and Marketing for Caliber Public Safety.

This significant upgrade reinforces the department’s commitment to modernizing public safety, ensuring the protection and well-being of O’Fallon’s 94,000+ residents. The integration of Caliber’s innovative technologies optimizes dispatch and response operations, facilitating faster reaction times and more effective data management.

“We are excited to leverage these cutting-edge tools to serve our community more efficiently and effectively,” said Chief Frank Mininni. “This technological leap ensures our teams can react faster and manage critical data more effectively, creating a more secure environment for everyone.”

Key benefits of the upgrade include:

Enhanced efficiency through seamless integration of CAD, Mobile, and RMS technologiesImproved data sharing capabilities, connecting local, regional, state, and national agenciesIncreased situational awareness for first responders through real-time access to critical information

The O’Fallon Police Department’s investment in Caliber Public Safety’s solutions was made possible by the “Use Tax” approved by voters in 2019. This tax enables the department to stay current with evolving technology, ensuring transparency and effective use of taxpayer money.

“We are honored to partner with the O’Fallon Police Department in their forward-thinking approach to public safety,” said Chris Faircloth, Vice President of Sales and Marketing for Caliber Public Safety. “Together, we are empowering their mission to enhance operational efficiency and safeguard the people they serve.”

About the O’Fallon Police Department:

The O’Fallon Police Department serves over 94,000 residents with a team of 100+ sworn officers, consistently ranking among America’s “Best Places to Live” and “Safest Cities.”

About Caliber Public Safety:

Caliber Public Safety provides innovative solutions to over 1,000 public safety agencies across North America, focusing on data-sharing and interoperability.

Media Contact

Chris Faircloth, Caliber Public Safety, 1-800-274-2911, info@caliberpublicsafety.com, https://caliberpublicsafety.com/

View original content:https://www.prweb.com/releases/ofallon-mo-police-department-revolutionizes-public-safety-with-cutting-edge-technology-with-caliber-public-safety-302307052.html

SOURCE Caliber Public Safety; Caliber Public Safety

Continue Reading

Technology

GAC Group Showcases New Energy Vehicles and Unveils “Panyu Action” at the 22nd Guangzhou International Auto Show

Published

4 hours ago

on

November 17, 2024

By

GUANGZHOU, China, Nov. 17, 2024 /PRNewswire/ — On November 15, at the 22nd Guangzhou International Auto Show, GAC’s self-owned brands unveiled three groundbreaking models. Alongside these vehicle debuts, GAC Group introduced its three-year strategic initiative – “Panyu Action” – which aims to increase the share of self-owned brands to over 60% of total group sales by 2027, targeting 2 million units in sales.

Designed to drive GAC Group’s transformation, “Panyu Action” is expected to enhance operational efficiency and position the company for sustained high-quality development. This strategic initiative is expected to help GAC strengthen its leadership within both domestic and international automotive markets.

Feng Xingya, President of GAC Group, stated, “GAC Group has taken a solid step forward in its new phase of transformation. We will forge ahead with determination and live up to expectations, presenting an all-new GAC to everyone over the next three years!”

In line with its vision, GAC Group has invested over 50 billion yuan in independent research and development. The company plans to invest an additional 50 billion yuan in the next three years to support its “Panyu Action” initiative, reinforcing its commitment to remain at the forefront of technological innovation in the automotive industry.

“Right now, GAC’s global expansion is entering a new phase, with vehicle exports and local production moving forward together,” said Wei Haigang, President of GAC International. ” We will continue to expand international markets, with plans to reach 100 countries and regions by 2027, and export 500,000 vehicles.”

As part of its growth strategy, GAC Group unveiled three standout models at this year’s auto show: the S7, GAC’s first advanced intelligent vehicle, featuring AI-driven ambient lighting with eight preset expressions for personalized interaction; the Aion UT, the third global strategic model from Aion, with bold headlights and a hatchback design that embodies a unique, free-spirited style; and the HYPTEC HL, GAC’s luxury intelligent flagship SUV, which combines yacht-style wraparound design with zero-gravity seats for an unmatched luxury electric driving experience.

These new models highlight GAC Group’s dedication to leading the smart electric vehicle market, with plans for their introduction to international markets as part of the company’s ongoing global expansion strategy.

Looking ahead, GAC Group remains committed to delivering better products, services, and experiences to consumers worldwide, enhancing mobility solutions and enriching the lives of customers across the globe.

SOURCE GAC

Continue Reading

Technology

Unmissable Black Friday Deals on Telegram Signal Copier: Significant Savings on Services, Trading Tools, and Exclusive Offers for Traders

Published

5 hours ago

on

November 17, 2024

By

As part of the Black Friday season, Telegram Signal Copier is offering traders exclusive discounts on services and advanced trading tools to support their strategies and enhance trading performance.

COVENT GARDEN, London, Nov. 17, 2024 /PRNewswire-PRWeb/ — Telegram Signal Copier (TSC), the most popular signal copier tool, is thrilled to announce exclusive discounts on a range of services and innovative trading tools designed to enhance trading strategies and improve overall performance for traders at every level.

A company spokesperson stated, “Our Black Friday specials offer significant savings, giving both new and experienced traders access to expert signals and tools. We’re confident these resources will empower users to make informed trading decisions and reach their financial goals.”

The Black Friday offers, originally scheduled for November 24 to November 30, are already live, providing traders with an exclusive early opportunity to access significant discounts. This early launch marks a unique chance for both novice and seasoned traders to refine their strategies and enhance their trading performance with major savings.

As part of this Black Friday season, Telegram Signal Copier is inviting traders to explore its specially curated packages that combine access to powerful trading tools and customized support services at a fraction of the cost. This limited-time event offers exclusive deals to support traders at every level, providing access to premium features that elevate trading strategies and outcomes.

This time TSC has also added an amazing feature that supports image signal copying, allowing traders to seamlessly replicate signals from image-based formats. Now this latest feature broadens the range of signals traders can access, providing greater flexibility and precision.

TSC Black Friday Offers Package 2024:

The Black Friday specials, available for a short window, will feature substantial savings across a wide range of offerings. Here’s a brief overview of the exceptional packages:

TSC Starter: Perfect for beginners interested in exploring the trading world with ease, TSC Starter offers essential tools and insights that simplify complex trading decisions, allowing new traders to start confidently.TSC Pro: This package is tailored for traders with some experience who want to deepen their strategies. With access to advanced tools, Pro users can gain deeper market insights to enhance trading outcomes.TSC Advance: The Advance package is the ultimate trading companion for experienced traders who demand the highest-quality tools and signals to support sophisticated trading strategies. It offers in-depth analyses, real-time insights, and expert-driven strategies designed to help maximize profits and minimize risks.

Whether you are an experienced trader or just beginning your trading journey, these deals are tailored to ensure you can benefit from expert signals and cutting-edge tools to enhance your trading performance. The Black Friday savings are not merely discounts.

So, traders are encouraged to mark their calendars for this exceptional Black Friday event and prepare to take advantage of TSC’s powerful trading solutions. This limited-time sale will allow traders to harness cutting-edge trading technology to optimize their strategies, making it a perfect time to elevate trading capabilities without the usual costs.

About Telegram Signal Copier:

Telegram Signal Copier is an acclaimed signal-copying tool in the trading community, enabling users to replicate expert trading signals directly in their accounts. Known for its intuitive interface, commitment to delivering accurate, timely market insights, and now its new image signal copying feature, TSC has established itself as an invaluable resource for traders seeking to elevate their trading experience. With a mission to provide accessible, top-tier trading resources, TSC empowers its users to thrive in the fast-paced world of Forex trading.

Media Contact

Nazrul Islam, Telegram Signal Copier, 44 2079461234, support@telegramsignalcopier.com, https://telegramsignalcopier.com/

View original content to download multimedia:https://www.prweb.com/releases/unmissable-black-friday-deals-on-telegram-signal-copier-significant-savings-on-services-trading-tools-and-exclusive-offers-for-traders-302306754.html

SOURCE Telegram Signal Copier

Continue Reading

Trending